Broadwood Partners Amends Oncocyte Stake
Ticker: IMDX · Form: SC 13D/A · Filed: Apr 15, 2024 · CIK: 1642380
Sentiment: neutral
Topics: shareholder-activity, sec-filing, amendment
Related Tickers: ONC
TL;DR
Broadwood Partners filed an update on their Oncocyte stake. Keep an eye on this one.
AI Summary
Broadwood Partners, L.P. has filed an amendment (No. 11) to its Schedule 13D concerning Oncocyte Corporation, as of April 15, 2024. The filing indicates changes in beneficial ownership of Oncocyte's common stock, though specific share counts and dollar amounts are not detailed in this header information.
Why It Matters
This filing signals a potential shift in significant shareholder interest or strategy regarding Oncocyte Corporation, which could influence the stock's performance.
Risk Assessment
Risk Level: medium — Schedule 13D filings often precede significant corporate actions or shifts in control, introducing potential volatility.
Key Players & Entities
- Broadwood Partners, L.P. (company) — Filing entity
- Oncocyte Corporation (company) — Subject company
- Neal C. Bradsher (person) — Contact person for Broadwood Partners
FAQ
What specific changes in beneficial ownership are detailed in this amendment?
The provided header information does not specify the exact number of shares or percentage change in beneficial ownership for Broadwood Partners, L.P. in Oncocyte Corporation.
What is the CUSIP number for Oncocyte Corporation's common stock?
The CUSIP number for Oncocyte Corporation's common stock is 68235C206.
When was this amendment filed with the SEC?
This amendment (No. 11) to Schedule 13D was filed on April 15, 2024.
Who is listed as the contact person for Broadwood Partners, L.P. regarding this filing?
Neal C. Bradsher, c/o Broadwood Capital, Inc., is listed as the contact person.
What is the primary business of Oncocyte Corporation?
Oncocyte Corporation operates in the 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES' industry, as indicated by its SIC code [2835].
Filing Stats: 2,213 words · 9 min read · ~7 pages · Grade level 8.9 · Accepted 2024-04-15 19:26:25
Key Financial Figures
- $7,057,688 — t”) for a total purchase price of $7,057,688, or $2.9164 per Share. In connection wi
- $2.9164 — total purchase price of $7,057,688, or $2.9164 per Share. In connection with Private P
Filing Documents
- d11029026_13d-a.htm (SC 13D/A) — 100KB
- 0000919574-24-002559.txt ( ) — 102KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: April 15, 2024 Broadwood Partners, L.P.* By: Broadwood Capital, Inc. By: /s/ Neal C. Bradsher Name: Neal C. Bradsher Title: President Broadwood Capital, Inc. * By: /s/ Neal C. Bradsher Name: Neal C. Bradsher Title: President /s/ Neal C. Bradsher Neal C. Bradsher * * This Reporting Person disclaims beneficial ownership over the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001). Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Amendment No. 11 to Schedule 13D, dated April 15, 2024, relating to the Common Stock, no par value, of Oncocyte Corporation shall be filed on behalf of the undersigned. Dated: April 15, 2024 Broadwood Partners, L.P. By: Broadwood Capital, Inc. By: /s/ Neal C. Bradsher Name: Neal C. Bradsher Title: President Broadwood Capital, Inc. By: /s/ Neal C. Bradsher Name: Neal C. Bradsher Title: President /s/ Neal C. Bradsher Neal C. Bradsher